昊帆生物：11月21日召开董事会会议

Group 1 - The core point of the article is that Haofan Bio (SZ 301393) held its 14th meeting of the 4th board of directors on November 21, 2025, to review documents including the proposal to amend the company's articles of association [1] - For the year 2024, Haofan Bio's revenue composition is entirely from the manufacturing of chemical raw materials and chemical products, accounting for 100.0% [1] - As of the time of reporting, Haofan Bio has a market capitalization of 5.4 billion yuan [1]